Treating VVA improves symptom severity and patient-reported outcomes: 6-month PEONY results

被引：0

作者：

Nappi, Rossella E. ^{[1
,2
]}

Meriggiola, Maria Cristina ^{[3
]}

Albani, Francesca ^{[4
]}

Bonaccorsi, Gloria ^{[5
]}

Carpini, Giovanni Delli ^{[6
]}

Gambera, Alessandro ^{[7
]}

Marsini, Silvia ^{[8
]}

Nicolucci, Antonio ^{[9
]}

Rossi, Maria Chiara ^{[9
]}

Trionfera, Valentina ^{[8
]}

Villa, Paola ^{[10
]}

机构：

[1] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy

[2] IRCCS S Matteo Fdn, Res Ctr Reprod Med & Gynecol Endocrinol, Menopause Unit, Piazzale Golgi 2, I-27100 Pavia, Italy

[3] IRCCS Azienda Osped Univ Bologna, Div Gynecol & Human Reprod Physiopatol, Bologna, Italy

[4] Ist Clin Sci Maugeri IRCCS, Gynecol Endocrinol Clin, Unit Endocrinol & Metab Dis, Pavia, Italy

[5] Univ Ferrara, Menopause & Osteoporosis Ctr, Ferrara, Italy

[6] Univ Politecn Marche, Dept Odontostomatol & Specialized Clin Sci, Gynecol Sect, Ancona, Italy

[7] Univ Brescia, ASST Sped Civili, Unit Gynecol Endocrinol, Brescia, Italy

[8] Shionogi Srl, Rome, Italy

[9] CORESEARCH Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy

[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Sci Salute Donna & Bambino & San Pubb, UOC Ginecol Oncol, Rome, Italy

来源：

CLIMACTERIC | 2025年 / 28卷 / 02期

关键词：

Vulvo-vaginal atrophy; local estrogens; non-hormonal local treatments; ospemifene; breast cancer; VULVO-VAGINAL ATROPHY; QUALITY-OF-LIFE; BREAST-CANCER SURVIVORS; FEMALE SEXUAL FUNCTION; GENITOURINARY SYNDROME; INDEX FSFI; WOMEN; MANAGEMENT; MENOPAUSE; HEALTH;

D O I：

10.1080/13697137.2025.2455167

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

ObjectiveThe real-world PatiEnt satisfactiON studY (PEONY) involves postmenopausal women already treated or starting local estrogen therapy (LET) or ospemifene. The aim of the present analysis was to assess treatment satisfaction and persistence, effectiveness and patient-reported outcomes (PROs) in sexual function and quality of life after 6 months of therapy with LET or ospemifene to treat vulvovaginal atrophy (VVA).MethodsPEONY is an ongoing prospective, observational study conducted in 17 gynecology centers. Participants complete questionnaires at baseline (T0) and after 3 months (T3) and 6 months (T6). The main outcome measures were treatment satisfaction, severity of symptoms, Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI), Female Sexual Distress Scale - Revised (FSDS-R) and SF-12 Health Survey.ResultsOverall, 385 women were included, of whom 145 started (87.6%) or continued (12.4%) ospemifene and 240 started (66.7%) or continued (33.3%) LET at T0. The likelihood of moderate/severe VVA symptoms decreased by 70-90% and the mean treatment satisfaction score increased overall from 7.3 (95% confidence interval [CI]: 7.0; 7.5) at T3 to 7.7 (95% CI: 7.4; 7.9) at T6 (p = 0.003). DIVA and FSDS-R scores significantly improved in both groups.ConclusionsPEONY underlines the importance of proactively treating VVA with LET or ospemifene to alleviate the burden associated with the disease. (sic)(sic): (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(PEONY)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(LET)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)LET(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(VVA)6(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(PROs).(sic)(sic): PEONY(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)17(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(T0),(sic)(sic)3(sic)(sic)(T3)(sic)(sic)(sic)6(sic)(sic)(T6)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(DIVA),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(FSFI),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(FSDS-R)(sic)SF-12(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic): (sic)(sic)(sic)(sic)(sic)(sic)385(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)145(sic)(sic)T0(sic)(sic)(sic)(87.6%)(sic)(sic)(sic)(12.4%)(sic)(sic)(sic)(sic)(sic)(sic), 240(sic)(sic)(sic)(66.7%)(sic)(sic)(sic)(33.3%)(sic)(sic)LET.(sic)(sic)6(sic)(sic)(sic), (sic)(sic)(sic)VVA(sic)(sic)(sic)(sic)(sic)(sic)(sic)70%-90%, (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)T3(sic)(sic)7.3(95%(sic)(sic)(sic)(sic)[CI]: 7.0;7.5)(sic)(sic)(sic)T6(sic)(sic)7.7(95% CI: 7.4;7.9)(p = 0.003).DIVA(sic)FSDS-R(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic): PEONY(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(LET)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(VVA)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).

引用

页码：115 / 125

页数：11

共 41 条

[1] The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society
不详
[J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (09): : 976 - 992
[2] Urogenital ageing: An old problem newly recognized
Bachmann, G
[J]. MATURITAS, 1995, 22 : S1 - S5
[3] Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?
Biglia, Nicoletta
Bounous, Valentina E.
Sgro, Luca G.
D'Alonzo, Marta
Pecchio, Silvia
Nappi, Rossella E.
[J]. CLINICAL BREAST CANCER, 2015, 15 (06) : 413 - 420
[4] Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy
Bruyniks, N.
Biglia, N.
Palacios, S.
Mueck, A. O.
[J]. CLIMACTERIC, 2017, 20 (03) : 195 - 204
[5] Lower urinary tract symptoms and their relation to vaginal atrophy in women across the menopausal age span. Results from the ANGEL multicentre observational study
Cagnacci, Angelo
Sclauzero, Martina
Meriggiola, Cristina
Xholli, Anjeza
[J]. MATURITAS, 2020, 140 : 8 - 13
[6] Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy
Constantine, Ginger D.
Bruyniks, Nico
Princic, Nicole
Huse, Daniel
Palmer, Liisa
Lenhart, Greg
Blumentals, William A.
Nappi, Rossella E.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (01) : 143 - 148
[7] Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause
Cox, P.
Panay, N.
[J]. CLIMACTERIC, 2023, 26 (04) : 367 - 372
[8] Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy
Cucinella, Laura
Tiranini, Lara
Cassani, Chiara
Martella, Silvia
Nappi, Rossella E.
[J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2023, 15 : 1261 - 1282
[9] Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder
DeRogatis, Leonard
Clayton, Anita
Lewis-D'Agostino, Diane
Wunderlich, Glen
Fu, Yali
[J]. JOURNAL OF SEXUAL MEDICINE, 2008, 5 (02) : 357 - 364
[10] The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe
DiBonaventura, Marco
Luo, Xuemei
Moffatt, Margaret
Bushmakin, Andrew G.
Kumar, Maya
Bobula, Joel
[J]. JOURNAL OF WOMENS HEALTH, 2015, 24 (09) : 713 - 722

← 1 2 3 4 5 →